Chemical function-based pharmacophore development for novel, selective kappa opioid receptor agonists

Journal of Molecular Graphics and Modelling

Volumn 27, Issue 2, 2008, Pages 131-139

  Singh, Nidhi ^a   Nolan, Tammy L ^a   McCurdy, Christopher R ^a,b  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Agonist; Analgesics; G protein coupled receptor (GPCR); Kappa opioid receptor; New chemical entities (NCEs); Peripherally restricted; Pharmacophore

Indexed keywords

ARSENIC COMPOUNDS; CHLORINE COMPOUNDS;

AGONIST; ANALGESICS; CENTRAL NERVOUS SYSTEM; CHEMICAL-; G-PROTEIN COUPLED RECEPTOR (GPCR); KAPPA OPIOID RECEPTOR; NEW CHEMICAL ENTITIES (NCES); OPIOID ANALGESICS; PERIPHERALLY RESTRICTED; PHARMACOPHORE; PHARMACOPHORE MODELING; SIDE EFFECTS; TRAINING SETS;

PHARMACODYNAMICS;

KAPPA OPIATE RECEPTOR AGONIST;

ALGORITHM; ARTICLE; CATALYST; CENTRAL NERVOUS SYSTEM; COMPUTER PROGRAM; COST BENEFIT ANALYSIS; DATA BASE; HYDROGEN BOND; HYDROPHOBICITY; PAIN; PHARMACOPHORE; PRIORITY JOURNAL; TARGET ORGAN;

ALGORITHMS; ANALGESICS; DRUG DESIGN; HUMANS; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PREDICTIVE VALUE OF TESTS; RECEPTORS, OPIOID, KAPPA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 52049125021     PISSN: 10933263     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmgm.2008.03.007     Document Type: Article

References (50)

1. Minami M., and Satoh M. Molecular biology of the opioid receptors: structures, functions and distributions. Neurosci. Res. 23 (1995) 121-145
2. Satoh M., and Minami M. Molecular pharmacology of the opioid receptors. Pharmacol. Ther. 68 (1995) 343-364
3. Millan M.J. Multiple opioid systems and pain. Pain 27 (1986) 303-347
4. Martin W.R. Pharmacology of opioids. Pharmacol. Rev. 35 (1983) 283-323
5. Martin W.R., Eades C.G., Thompson J.A., Huppler R.E., and Gilbert P.E. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197 (1976) 517-532
6. Pande A., Pyke R.E., Greiner M., Cooper S.A., Benjamin R., and Peirce M.W. Analgesic efficacy of the κ-receptor agonist, enadoline, in dental surgery pain. Clin. Neuropharmacol. 19 (1996) 92-97
7. Pande A., Pyke R.E., Greiner M., Wideman G.L., Benjamin R., and Pierce M.W. Analgesic efficacy of enadoline versus placebo or morphine in postsurgical pain. Clin. Neuropharmacol. 19 (1996) 451-456
8. Kumar V., Marella M.A., Cortes-Burgos L., et al. Arylacetamides as peripherally restricted kappa opioid receptor agonists. Bioorg. Med. Chem. Lett. 10 (2000) 2567-2570
9. Zhang Q., Schaffer M., Elde R., and Stein C. Effects of neurotoxins and hindpaw inflammation on opioid receptor immunoreactivities in dorsal root ganglia. Neuroscience 85 (1998) 281-291
10. Riviere P.J. Peripheral kappa-opioid agonists for visceral pain. Br. J. Pharmacol. 141 (2004) 1331-1334
11. Shaw J., Carroll J.A., Alcock P., and Main B.G. ICI 204448: a kappa-opioid agonist with limited access to the CNS. Br. J. Pharmacol. 96 (1989) 986-992
12. Bickel A., Dorfs S., Schmelz M., Forster C., Uhl W., and Handwerker H.O. Effects of antihyperalgesic drugs on experimentally induced hyperalgesia in man. Pain 76 (1998) 317-325
13. Kramer H., Uhl W., Ladstetter B., and Backer A. Influence of asimadoline, a new κ-opioid receptor agonist, on tubular water absorption and vasopressin secretion in man. Br. J. Pharmacol. 50 (2000) 227-235
14. Machelska H., Pfluger M., Weber W., et al. Peripheral effects of the κ-opioid agonist EMD 61753 on pain and inflammation in rats and humans. J. Pharmacol. Exp. Ther. 290 (1999) 354-361
15. Chang A.C., Cowan A., Takemori A.E., and Portoghese P.S. Aspartic acid conjugates of 2-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1(3-aminophenyl)-2-(1-pyrrolidinyl) ethyl]acetamide: kappa opioid receptor agonists with limited access to the central nervous system. J. Med. Chem. 39 (1996) 4478-4482
16. DeHaven-Hudkins D.L., and Dolle R.E. Peripherally restricted opioid agonists as novel analgesic agents. Curr. Pharm. Des. 10 (2004) 743-757
17. Kumar V., Guo D., Cassel J.A., et al. Synthesis and evaluation of novel peripherally restricted kappa-opioid receptor agonists. Bioorg. Med. Chem. Lett. 15 (2005) 1091-1095
18. Catalyst, version 4.8, Burlington, Accelrys Inc., 2003.
19. Chu G.H., Gu M., Cassel J.A., et al. Potent and highly selective kappa opioid receptor agonists incorporating chroman- and 2,3-dihydrobenzofuran-based constraints. Bioorg. Med. Chem. Lett. 15 (2005) 5114-5119
20. Le Bourdonnec B., Ajello C.W., Seida P.R., et al. Arylacetamide kappa opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity. Bioorg. Med. Chem. Lett. 15 (2005) 2647-2652
21. Ronsisvalle G., Prezzavento O., Pasquinucci L., et al. CCB, a novel specific kappa opioid agonist, which discriminates between opioid and sigma 1 recognition sites. Life Sci. 57 (1995) 1487-1495
22. Tuthill P.A., Seida P.R., Barker W., et al. Azepinone as a conformational constraint in the design of kappa-opioid receptor agonists. Bioorg. Med. Chem. Lett. 14 (2004) 5693-5697
23. Walsh S.L., Strain E.C., Abreu M.E., and Bigelow G.E. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl.) 160 (2001) 170-181
24. Hunter J.C., Leighton G.E., Meecham K.G., et al. CI-977, a novel and selective agonist for the kappa-opioid receptor. Br. J. Pharmacol. 101 (1990) 183-189
25. Clark C.R., Halfpenny P.R., Hill R.G., et al. Highly selective kappa opioid analgesics. Synthesis and structure-activity relationships of novel N-[2-aminocyclohexylaryl]acetamide and N-[2-aminocyclohexylaryloxy]acetamide derivatives. J. Med. Chem. 31 (1988) 831-836
26. Siener T., Cambareri A., Kuhl U., et al. Synthesis and opioid receptor affinity of a series of 2, 4-diaryl-substituted 3,7-diazabicylononanones. J. Med. Chem. 43 (2000) 3746-3751
27. Cappelli A., Anzini M., Vomero S., et al. Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors. J. Med. Chem. 39 (1996) 860-872
28. Giardina G., Clarke G.D., Dondio G., Petrone G., Sbacchi M., and Vecchietti V. Selective kappa-opioid agonists: synthesis and structure-activity relationships of piperidines incorporating on oxo-containing acyl group. J. Med. Chem. 37 (1994) 3482-3491
29. Ronsisvalle G., Marrazzo A., Pasquinucci L., Prezzavento O., Pappalardo M., and Vittorio F. Specific kappa opioid receptor agonists. Farmaco 56 (2001) 121-125
30. Vecchietti V., Clarke G.D., Colle R., Giardina G., Petrone G., and Sbacchi M. (1S)-1-(Aminomethyl)-2-(arylacetyl)-1,2,3,4-tetrahydroisoquinoline and heterocycle-condensed tetrahydropyridine derivatives: members of a novel class of very potent kappa opioid analgesics. J. Med. Chem. 34 (1991) 2624-2633
31. Halfpenny P.R., Hill R.G., Horwell D.C., et al. Highly selective kappa-opioid analgesics. Part 2. Synthesis and structure-activity relationships of novel N-[(2-aminocyclohexyl)aryl]acetamide derivatives. J. Med. Chem. 32 (1989) 1620-1626
32. Kumar V., Guo D., Daubert J.D., et al. Amino acid conjugates as kappa opioid receptor agonists. Bioorg. Med. Chem. Lett. 15 (2005) 1279-1282
33. Soukara S., Maier C.A., Predoiu U., Ehret A., Jackisch R., and Wunsch B. Methylated analogues of methyl (R)-4-(3,4-dichlorophenylacetyl)-3-(pyrrolidin-1-ylmethyl)piperazine-1-carboxylate (GR-89,696) as highly potent kappa-receptor agonists: stereoselective synthesis, opioid-receptor affinity, receptor selectivity, and functional studies. J. Med. Chem. 44 (2001) 2814-2826
34. Szmuszkovicz J., and Von Voigtlander P.F. Benzeneacetamide amines: structurally novel non-mu opioids. J. Med. Chem. 25 (1982) 1125-1126
35. Guner O., Clement O., and Kurogi Y. Pharmacophore modeling and three dimensional database searching for drug design using Catalyst: recent advances. Curr. Med. Chem. 11 (2004) 2991-3005
36. Gund P. Progress in Molecular and Subcellular Biology (1977), Springer-Verlag, New York
37. Brooks B.R., Bruccoleri R.E., Olafson B.D., States D.J., Swaminathan S., and Karplus M. CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 4 (1983) 187-217
38. Smellie A., Teig S.L., and Towbin P. Poling: promoting conformational variation. J. Comput. Chem. 16 (1995) 171-187
39. English Philosopher and Franciscan Monk, William of Ockham, p. 1285.
40. Sutter J., Guner O.F., Hoffman R., Li H., and Waldman M. Pharmacophore: Perception, Development and Use in Drug Design (1999), International University Line, La Jolla
41. Fischer R. The Design of Experiments. 8th ed. (1966), Hafner Publishing Co., New York
42. Lavecchia A., Greco G., Novellino E., Vittorio F., and Ronsisvalle G. Modeling of kappa-opioid receptor/agonists interactions using pharmacophore-based and docking simulations. J. Med. Chem. 43 (2000) 2124-2134
43. Metzger T.G., Paterlini M.G., Portoghese P.S., and Ferguson D.M. Application of the message-address concept to the docking of naltrexone and selective naltrexone-derived opioid antagonists into opioid receptor models. Neurochem. Res. 21 (1996) 1287-1294
44. Iadanza M., Holtje M., Ronsisvalle G., and Holtje H.D. Kappa-opioid receptor model in a phospholipid bilayer: molecular dynamics simulation. J. Med. Chem. 45 (2002) 4838-4846
45. Subramanian G., Paterlini M.G., Larson D.L., Portoghese P.S., and Ferguson D.M. Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists. J. Med. Chem. 41 (1998) 4777-4789
46. Wan X.H., Huang X.Q., Zhou D.H., Jiang H.L., Chen K.X., and Chi Z.Q. Building 3D-structural model of kappa opioid receptor and studying its interaction mechanism with dynorphin A(1-8). Acta Pharmacol. Sin. 21 (2000) 701-708
47. Holzgrabe U., and Brandt W. Mechanism of action of the diazabicyclononanone-type kappa-agonists. J. Med. Chem. 46 (2003) 1383-1389
48. Filizola M., Villar H.O., and Loew G.H. Differentiation of delta, mu, and kappa opioid receptor agonists based on pharmacophore development and computed physicochemical properties. J. Comput. Mol. Des. 15 (2001) 297-307
49. Singh N., Chevé G., Ferguson D.M., and McCurdy C.R. A combined ligand-based and target-based drug design approach for G-protein coupled receptors: application to salvinorin A, a selective kappa opioid receptor agonist. J. Comput. Mol. Des. 20 (2006) 471-493
50. Kane B., Nieto M., McCurdy C., and Ferguson D. A unique binding epitope for salvinorin A, a non-nitrogenous kappa opioid receptor agonist. FEBS J. 273 (2006) 1966-1974